Abstract 2112: COLD-PCR -Based Deep Sequencing Identifies Novel Mutations and Intratumor TP53 Mutational Heterogeneity in Lung Adenocarcinoma

Jin Li,Coren A. Milbury,Cheng Li,Mike G. Makrigiorgos

DOI: https://doi.org/10.1158/1538-7445.am10-2112

IF: 11.2

2010-01-01

Cancer Research

Abstract:Abstract TP53 is frequently mutated in lung adenocarcinoma, a major type of lung cancer, and certain TP53 mutations correlate with prognosis and multidrug resistance. Reliable identification of the type and position of TP53 mutations is problematic as the mutations are scattered over numerous codons while their abundance in clinical samples can fall below the sensitivity limits of conventional sequencing methods. Here we employ COLD-PCR, a new form of PCR that selectively amplifies mutation-containing sequences such that the resulting PCR products contain high percentages of mutant alleles. To ensure the highest sensitivity, we adapted the method to employ two consecutive rounds of COLD-PCR followed by Sanger sequencing. Using this highly sensitive new approach for ‘deep-sequencing’ we screened 48 lung adenocarcinoma samples to identify presence and type/position of low-level TP53 mutations. Missense/frame-shift TP53 mutations throughout exons 5-8 were identified in 23 out of 48 (48%) lung adenocarcinoma samples examined, including 8 low-level mutations with an abundance of 1-17% and 3 with an abundance below 1%. 3 novel lung adenocarcinoma mutations were discovered. We identified disruptive mutations that are undocumented in the lung cancer TP53 mutation database and samples harboring low-level (2%-abundance) putative driver mutations concurrently with passenger clonal TP53 mutations (80%-abundance). Our data reveal the presence of widespread intra-tumoral TP53 mutation heterogeneity, and a spectrum of numerous protein-altering mutations at low abundance, that were missed in previous investigations. The implications of using deep-TP53-sequencing as a prognostic/predictive biomarker, evaluation of cancer risk, recurrence, and further understanding of cancer biology are discussed. In addition, we evaluate the use of whole genome-amplification prior to mutation screening in situations when the source of genomic DNA is limited, which can be critical for early cancer detection from biopsy, the assessment of minimal residual disease following surgery, disease staging, and monitoring of cancer progression. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 2112.